Crossmark

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

Crossref DOI link: https://doi.org/10.1038/leu.2015.220

Published Online: 2015-09-15

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dinmohamed, A G

van Norden, Y

Visser, O

Posthuma, E F M

Huijgens, P C

Sonneveld, P

van de Loosdrecht, A A

Jongen-Lavrencic, M
License Information

Text and Data Mining valid from 2015-09-15

Version of Record valid from 2015-09-15
More Information

Article History

First Online: 15 September 2015

Competing interests

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below